A carbonyl reductase mutant for preparing chiral β-tetrahydronaphthol drug intermediates
By directionally reconstructing the carbonyl reductase of Pachysolen tannophilus and introducing specific amino acid mutations, the problems of low catalytic activity and limited stereoselectivity of the wild-type enzyme were solved, enabling the efficient preparation of chiral β-tetrahydronaphthol, which is suitable for the synthesis of key chiral precursors such as rotigotine, an anti-Parkinson's disease drug.
Patent Information
- Application Number
- CN202611119848.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-27
- Publication Date
- 2026-11-17
AI Technical Summary
In the preparation of chiral β-tetrahydronaphthol, existing technologies suffer from low catalytic activity of wild-type carbonyl reductases and severe steric hindrance of substrates, making it difficult to achieve efficient and flexible stereoselective regulation and failing to meet the requirements of enantiomers in medicinal chemistry.
By directionally reconstructing Pachysolen tannophilus carbonyl reductase and introducing specific amino acid mutations, such as L247K, I171L, and H167V, steric hindrance can be overcome, catalytic activity can be enhanced, and precise control over the stereoconfiguration of the product can be achieved.
It significantly improved the conversion efficiency and stereoselectivity of β-tetrahydronaphthone, and significantly increased the yield and ee value of the mutant products in both S- and R-configurations. It achieved a highly efficient and environmentally friendly biocatalytic process, avoiding the cumbersome steps and heavy metal residue risks of traditional chemical synthesis.
Smart Images

Figure CN123107943A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a carbonyl reductase mutant for preparing chiral β-tetrahydronaphthol drug intermediates, belonging to the fields of enzyme engineering and genetic engineering technology. Background Technology
[0002] Chiral β-tetrahydronaphthol (2-tetralol) and its derivatives with substituents (such as methoxy, hydroxyl, or halogen) on the ring are indispensable core chiral building blocks in the modern pharmaceutical industry. Clinical studies and medicinal chemistry have confirmed that the β-tetrahydronaphthol skeleton with different substitution modes and stereoconfigurations determines the specific targeting of drugs: for example, (S)-5-methoxy-2-tetrahydronaphthol is a key chiral precursor in the synthesis of the blockbuster anti-Parkinson's disease drugs rotigotine and quinagolide; while halogenated derivatives such as chiral 6-bromo-2-tetrahydronaphthol are the core module in the synthesis of the potent antiarrhythmic drug MK-0499; in addition, (R)-8-bromo-2-tetrahydronaphthol is widely used in the synthesis of the antidepressant and anti-anxiety targeted drug AR-A2. Since the treatment of central nervous system (CNS) related diseases has a stringent recognition mechanism for the stereoconfiguration of drug molecules, developing technical routes that can efficiently and stereoselectively obtain (S)- and (R)-β-tetrahydronaphthol has enormous economic value and industrial application potential.
[0003] Currently, the industry still heavily relies on traditional chemical synthesis or racemic resolution processes when constructing such chiral centers. Traditional chemical asymmetric synthetic routes are extremely lengthy (often requiring more than eight linear steps), often necessitating the introduction of expensive chiral auxiliaries (such as chiral amines) for stereoinduction. Furthermore, the critical reduction step often requires harsh ultra-low temperatures of -78 °C, resulting in poor atom economy and often unsatisfactory yields in the first reduction step. In addition, classic resolution strategies for racemic products (such as using D-tartaric acid crystallization) theoretically yield only up to 50%, often resulting in over 75% material waste in actual processes, leading to a final overall yield frequently below 5%, and carrying the risk of heavy metal residues, making it difficult to meet modern green pharmaceutical standards.
[0004] Utilizing biocatalysts to achieve direct asymmetric reduction of carbonyl groups is an ideal approach to circumvent the aforementioned bottlenecks. However, existing biocatalytic technologies still have significant limitations: on the one hand, early natural enzyme libraries (such as transaminases or partial reductases) lack sufficient evolution for sterically hindered substrates, resulting in a narrow substrate spectrum and difficulty in catalyzing specific aromatic ring substitution of tetrahydronaphthone substrates; on the other hand, existing enzyme libraries often exhibit stereoselectivity limitations, typically providing only one of the (S)- or (R)- configurations, failing to meet the needs of medicinal chemistry for comprehensive structure-activity evaluation of enantiomers. Particularly for β-tetrahydronaphthone and its analogues, wild-type reductases are prone to falling into a "catalytically dead state" due to the significant steric constraints and large steric hindrance of the substrates. Therefore, for sterically hindered fused-ring substrates such as β-tetrahydronaphthone, there is an urgent need to develop a novel enzymatic platform that can flexibly regulate stereoselectivity, overcome steric hindrance limitations, and achieve high spatial convergence. Summary of the Invention
[0005] To address the shortcomings of the aforementioned wild-type carbonyl reductase (WT) in catalyzing the conversion of β-tetrahydronaphthylone to chiral β-tetrahydronaphthol, which suffers from extremely low catalytic activity (conversion rate of only 2.5% at a substrate concentration of 5 mM) due to substrate steric hindrance and non-productive binding, this invention employs enzyme engineering techniques to target enzymes derived from... Pachysolen tannophilus The carbonyl reductase (PatCR) was reconstructed in a directed manner. The mutant provided by this invention not only successfully broke the catalytic dead state of the wild-type enzyme, significantly improving the conversion efficiency of the sterically hindered condensed ring substrate β-tetrahydronaphthone, but also achieved precise bidirectional regulation of the product stereoconfiguration (S or R).
[0006] This invention is achieved through the following technical solution: The first objective of this invention is to provide a method for preparing chiral β-tetrahydronaphthol, wherein the method uses a carbonyl reductase mutant as a catalyst to catalyze an asymmetric reduction reaction of β-tetrahydronaphthone to prepare chiral β-tetrahydronaphthol; wherein the amino acid sequence of the carbonyl reductase mutant is: (1) An amino acid sequence obtained by performing one or more positional mutations on the wild-type amino acid sequence SEQ ID NO. 1; (2) or an amino acid sequence that has more than 90% (preferably more than 95%) homology with the sequence after mutation of (1) above, and has the activity of catalyzing the generation of the corresponding chiral alcohol from β-tetrahydronaphthone.
[0007] The amino acid sequence (SEQ ID NO. 1) of wild-type carbonyl reductase (WT) is as follows: MSATTVLVTGASGFVALHVVDVLLSKNYPVIGTVRSAEKGDKILKQFQTKYPNATLRFEIVKDIAEEGAFDEVLKQNKGIKYVLHTASPFSFGFETSPEDAYLKPAVEGTLNVLKAIKKYAPQVTNVIITSSFASVLNYDKVADQSFIHTEKTWNPITWEQARVDEHAAYIASKTLAE KAAWDFVEKEKPSFELTTLLPPYIFGPQVFEDALQSGKLNTSCELINDVLKTNPGDGADDPTKFTKDGLLSVDVRDVALFHVLAFEKNLGNKRLFPVQGKFSQQAFLNIVNKDFPELKGKIATGTPQAAEDALKSYPAYDNSESAKLTGVQFIPLEKSVVDTVQQILHYKKKHGLPLK In one embodiment of the present invention, in the system of the asymmetric reduction reaction, the concentration of the substrate β-tetrahydronaphthone is 5-10 mM, the concentration of the coenzyme NADPH is 5-10 mM, the reaction temperature is 20-30 ℃, and the pH of the buffer solution is 6.0-8.5.
[0008] A second objective of this invention is to provide a carbonyl reductase mutant obtained by single-point or multi-point combination mutation of the sequence shown in SEQ ID NO. 1.
[0009] In one embodiment of the present invention, the mutant is a mutant that targets the generation of (S)-β-tetrahydronaphthol, and the mutant is selected from any one of the following: single-point mutations L247K, I171L, or I171N; combined mutations L247K-I171L, L247K-I171N, L247H-H167I, L247M-H167V, or L247M-H167I.
[0010] In one embodiment of the present invention, the mutant is a mutant that targets the generation of (R)-β-tetrahydronaphthol, and the mutant is selected from any one of the following: single-point mutations H167V, H167I, L247H or L247M.
[0011] A third objective of this invention is to provide a gene encoding the aforementioned mutant.
[0012] A fourth objective of this invention is to provide a recombinant expression vector carrying the gene.
[0013] In one embodiment of the present invention, the recombinant expression vector includes, but is not limited to, pET-32a(+), pET-28a or pET-22b, preferably pET-32a(+).
[0014] A fifth objective of this invention is to provide a recombinant microbial cell expressing the carbonyl reductase mutant, carrying the gene, or carrying the recombinant expression vector.
[0015] In one embodiment of the present invention, the recombinant microbial cell uses bacteria or fungi as the host cell.
[0016] In one embodiment of the present invention, the recombinant microbial cells are Escherichia coli, Bacillus subtilis, or yeast as host cells.
[0017] Preferably, the host cell is Escherichia coli Rosetta2 (DE3).
[0018] The sixth objective of this invention is to provide a method for improving the catalytic activity of carbonyl reductase for β-tetrahydronaphthone and regulating stereoselectivity.
[0019] In one embodiment of the present invention, the method comprises spatially converging and reshaping the binding pocket key site of wild-type enzyme SEQ ID NO.1: Introducing mutations at positions 247 or 171, or through a combination of mutations at positions 247 and 171, or 167, can significantly enhance the catalytic activity of carbonyl reductase for β-tetrahydronaphthol and yield products primarily composed of (S)-β-tetrahydronaphthol. Introducing mutations at positions 167 or 247 can alter the substrate binding mode, resulting in a conversion of the product configuration toward (R)-β-tetrahydronaphthol.
[0020] A seventh object of the present invention is to provide the use of the carbonyl reductase mutant, the recombinant expression vector carrying the gene, or the microbial cell in the preparation of chiral β-tetrahydronaphthol and chiral pharmaceutical intermediates.
[0021] In one embodiment of the present invention, the application involves adding the carbonyl reductase mutant or the microbial cell to a reaction system containing the substrate β-tetrahydronaphthone, the coenzyme NADPH and a buffer solution to prepare chiral β-tetrahydronaphthol with (S)- or (R)- configuration.
[0022] When the carbonyl reductase mutant is a single-point mutation L247K, I171L, I171N, or a combination mutation L247K-I171L, L247K-I171N, L247H-H167I, L247M-H167V, L247M-H167I, the product generated is (S)-β-tetrahydronaphthol. When the carbonyl reductase mutant is a single-point mutation H167V, H167I, L247H, or L247M, an absolute configuration inversion occurs, and the product is (R)-β-tetrahydronaphthol.
[0023] In one embodiment of the present invention, in the reaction system, the final concentration of the substrate β-tetrahydronaphthone is 5-10 mM, the concentration of the coenzyme NADPH is 5-10 mM, the pH of the buffer solution is 6.0-8.5, and the reaction is carried out at 20-40 °C and 100-300 rpm for 24-36 h.
[0024] In one embodiment of the present invention, the chiral pharmaceutical intermediate is specifically used to prepare a chiral precursor for the synthesis of Rotigotine, AR-A2, Quinagolide, or MK-0499.
[0025] The eighth object of the present invention is to provide a method for constructing the mutant.
[0026] In one embodiment of the present invention, the construction method includes the following steps: codon optimization, vector construction, site-directed / combinatorial mutation introduction, engineered bacterial transformation, temperature-induced expression, and cell disruption and extraction.
[0027] The ninth objective of this invention is to provide a method for overcoming the steric hindrance of substrates catalyzed by wild-type carbonyl reductase and achieving configuration inversion. The method involves mutating the carbonyl reductase mutant to the wild-type carbonyl reductase with the amino acid sequence shown in SEQ ID NO. 1. The mutation is as follows: mutating leucine at position 247 of the wild-type enzyme to lysine, histidine, or methionine; or mutating isoleucine at position 171 of the wild-type enzyme to leucine or asparagine; or mutating histidine at position 167 of the wild-type enzyme to valine or isoleucine; or mutating leucine at position 247 of the wild-type enzyme to lysine and simultaneously mutating isoleucine at position 171 to leucine or asparagine; or mutating leucine at position 247 of the wild-type enzyme to histidine and simultaneously mutating histidine at position 167 to isoleucine; or mutating leucine at position 247 of the wild-type enzyme to methionine and simultaneously mutating histidine at position 167 to valine or isoleucine.
[0028] The tenth object of the present invention is to provide the use of the above-mentioned carbonyl reductase mutant, or the above-mentioned gene, or the above-mentioned recombinant expression vector, or the above-mentioned microbial cell in the preparation of a drug or a drug intermediate.
[0029] Preferably, the drug is an antifungal drug or an antiarrhythmic drug.
[0030] Preferably, the pharmaceutical intermediate is an antifungal pharmaceutical intermediate or an antiarrhythmic pharmaceutical intermediate.
[0031] Preferably, the drug includes, but is not limited to, liranafate, 5,6,7,8-tetrahydro-2-naphthol, udimide, MK-0499, (S)-2-tetrahydronaphthol, 6-hydroxy-2-tetrahydronaphthol, 2-aminotetrahydronaphthol, β-tetrahydronaphthone, rotigotine, AR-A2, quinagolide, naphthone derivatives, and tetrahydronaphth-2-ol derivatives.
[0032] Beneficial effects Compared to existing technologies, this invention utilizes the source... Pachysolen tannophilus By molecularly modifying the wild-type carbonyl reductase (PatCR), the severe defects of "steric hindrance" and "non-productive binding" existing in the wild-type enzyme when catalyzing sterically hindered fused-ring substrates have been successfully overcome, resulting in the following significant industrialization advantages and beneficial effects: (1) Successfully overcame the "catalytic dead state" of sterically hindered substrates, achieving an exponential leap in catalytic activity. In a specific catalytic reaction system, the wild-type enzyme WT-PatCR catalyzed a product yield of only 2.50% for the conversion of β-tetrahydronaphthol from β-tetrahydronaphthone. Compared with the wild-type enzyme, the multiple carbonyl reductase mutants provided in this invention significantly improved the asymmetric reduction ability of β-tetrahydronaphthone. For example, the product yield of the single-site mutant L247K increased to 90.92%, I171L to 100.00%, and I171N to 99.76%; the product yields of the combined mutants L247K-I171L and L247K-I171N both reached 100.00%. These results indicate that by mutating key sites of the wild-type carbonyl reductase, its efficiency in catalyzing the preparation of chiral β-tetrahydronaphthol from β-tetrahydronaphthone can be significantly improved.
[0033] (2) It has achieved extremely rare and remarkable stereoselective precision control. Existing natural enzymes are often limited by single stereoselectivity, while this invention, based on the same carbonyl reductase backbone system, achieves regulation of the asymmetric reduction activity and product conformation of β-tetrahydronaphthol through key site mutations. The wild-type enzyme WT-PatCR mainly produces the S-configuration β-tetrahydronaphthol with an ee value of 99%, but the product yield is only 2.50%. Compared with the wild-type enzyme, mutants targeting the S-configuration product significantly improve product yield. For example, L247K increases the product yield to 90.92% with an ee value of 99%; I171L achieves a product yield of 100.00% with an ee value of 99%; and I171N achieves a product yield of 99.76% with an ee value of 98.75%. The combined mutants L247K-I171L and L247K-I171N both achieve a product yield of 100.00% with an ee value of 99%. Furthermore, some mutants of this invention can alter the stereoselectivity of the wild-type enzyme, achieving regulation of the product configuration from S to R. Mutants H167V, H167I, L247H, and L247M primarily produce the R configuration product. Specifically, H167V has an ee value of 85.44% and a product yield of 97.42%; H167I has an ee value of 79.68% and a product yield of 99.00%; L247H has an ee value of 50.75% and a product yield of 99.00%; and L247M has an ee value of 77.15% and a product yield of 76.66%. These results indicate that amino acid mutations at positions 167, 171, and 247 can enhance the catalytic activity of carbonyl reductase for β-tetrahydronaphthol and regulate the S / R configuration of the β-tetrahydronaphthol product.
[0034] (3) Compared with the cumbersome multi-step reaction, harsh ultra-low temperature conditions (-78°C), and dependence on expensive chiral auxiliary agents in traditional chemical asymmetric reduction methods, the bio-enzymatic process of this invention has mild conditions, does not require the introduction of any chiral auxiliary groups, and can efficiently reduce sterically hindered substrates in one step. This fundamentally avoids the subsequent high-pressure deprotection step and the risk of heavy metal (such as palladium on carbon) residues, greatly improving atom economy. It provides a green biomanufacturing solution with great cost advantages and environmental benefits for key chiral precursors of blockbuster central nervous system drugs (such as the anti-Parkinson's disease drug Rotigotine, the antidepressant AR-A2, and the antiarrhythmic drug MK-0499). Attached Figure Description
[0035] Figure 1 This is a schematic diagram illustrating the generation of chiral β-tetrahydronaphthol from β-tetrahydronaphthol by carbonyl reductase (PatCR) and mutants.
[0036] Figure 2A , Figure 2B , Figure 2C , Figure 2D The image shows the SDS-PAGE protein gel electrophoresis results of β-tetrahydronaphthone on carbonyl reductase (PatCR) and mutants. Detailed Implementation
[0037] The present invention will be further illustrated below with specific examples. These embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Furthermore, after reading the teachings of this invention, those skilled in the art can make various alterations or modifications to the invention, and these equivalent forms also fall within the scope defined by the appended claims.
[0038] The culture media and solutions mentioned below are as follows: TB liquid culture medium (mg / mL): yeast extract 24, tryptone 12, K2HPO4 12.54, KH2PO4 2.31, glycerol 4 (mL / L). TB solid medium (mg / mL): yeast extract 24, tryptone 12, K2HPO4 12.54, KH2PO4 2.31, glycerol 4 (mL / L), agar powder 15.
[0039] Protein purification solution A: 100 mM PBS, 20 mM imidazole, pH adjusted to 7.5 with hydrochloric acid. Protein purification solution B: 100 mM PBS, 350 mM imidazole, pH adjusted to 7.5 with hydrochloric acid. Desalting / reaction buffer: 100 mM PBS buffer, pH 7.0-7.4. (Note: When culturing E. coli Rosetta2(DE3) containing recombinant plasmids, ampicillin and chloramphenicol at a final concentration of 100 μg / mL and chloramphenicol at 34 μg / mL should be added to the culture medium.)
[0040] The conventional biological operation methods and detection methods involved in the following examples are as follows: The competent cells (such as E. coli Rosetta2(DE3) competent cells) and related plasmid extraction kits used in the embodiments of this invention are all commercially available products. Basic molecular biology operations such as plasmid chemical transformation and E. coli culture were performed in accordance with the standard operating procedures in "Molecular Cloning: A Laboratory Manual" or the product instructions.
[0041] The catalytic detection methods involved in the following examples are as follows: Conversion rate and stereoselectivity (ee value) determination: After the reaction, ethyl acetate (3 times its volume) was added to the reaction system for extraction. The organic phase was separated by vortexing and centrifugation, and then evaporated to dryness using a vacuum concentrator. An equal volume of mobile phase was added for redissolution. The supernatant organic phase was filtered through a 0.22 μm organic filter membrane and analyzed by supercritical carbon dioxide fluid chromatography (UPCC) or high-performance liquid chromatography (HPLC).
[0042] Supercritical carbon dioxide fluid chromatography (UPCC) or high-performance liquid chromatography (HPLC) were used for quantitative and configurational analysis of substrates and products in the organic phase. UPCC detection conditions: column: AMY-1 column, column temperature: 40 ℃, flow rate: 2 mL / min, mobile phase: 95% CO2 and 5% isopropanol; HPLC detection conditions: column: ADH column, column temperature: 40 ℃, flow rate: 0.8 mL / min, mobile phase: 95% n-hexane and 5% isopropanol.
[0043] Conversion rate (%) = ([initial substrate concentration] - [final substrate concentration]) / [initial substrate concentration] × 100%.
[0044] Enantiomer excess ee (%) = ([Main configuration product] - [Minor configuration product]) / ([Main configuration product] + [Minor configuration product]) × 100% (Note: The ee value is positive when the product is (S)-configuration, and negative when the absolute configuration is reversed to generate a pure (R)-configuration product).
[0045] Methods for determining carbonyl reductase activity Enzyme activity was measured by real-time monitoring of the rate of decrease in absorbance of the coenzyme NADPH at 340 nm using a microplate reader. The reaction system was preheated to 30 °C. The reaction system contained 100 mM PBS buffer (pH 7.2-7.4), 5 mM substrate, and 0.5 mM NADPH. Subsequently, 20 μL of purified enzyme solution (maintaining a final protein concentration of 0.50 mg / mL) was rapidly added to the system to initiate the reaction. The change in absorbance at 340 nm was continuously monitored, and the absorbance decrease during the initial linear reaction phase (e.g., within 1-3 min) was recorded.
[0046] The enzyme activity unit (U) is defined as follows: under the above standard determination conditions, the amount of enzyme that can reduce NADPH in the reaction system by 1 μmol per minute is defined as 1 enzyme activity unit, i.e., 1 U.
[0047] Specific activity (U / mg) = Measured enzyme activity (U) / Amount of protein added to the system (mg).
[0048] Purified target protein concentration Quantitative calculations are performed by measuring the absorbance at 280 nm using a micro-spectrophotometer (such as NanoDrop) (A280 method).
[0049] The technical solution of the present invention will be described in detail below with reference to specific embodiments. In the following embodiments, unless otherwise specified, the reagents, materials and equipment used can be purchased commercially or prepared using conventional methods commonly used in the industry.
[0050] Example 1: Construction of recombinant bacteria containing wild-type and mutant carbonyl reductase (1) Construction of expression vector and recombinant bacteria containing wild-type carbonyl reductase (PatCR) Will come from Pachysolen tannophilus Based on the amino acid sequence information of carbonyl reductase (SEQ ID NO.1), codon optimization was performed according to the codon preference rules of Escherichia coli to obtain the optimized wild-type carbonyl reductase gene sequence.
[0051] The amino acid sequence of the wild-type enzyme (SEQ ID NO.1): MSATTVLVTGASGFVALHVVDVLLSKNYPVIGTVRSAEKGDKILKQFQTKYPNATLRFEIVKDIAEEGAFDEVLKQNKGIKYVLHTASPFSFGFETSPEDAYLKPAVEGTLNVLKAIKKYAPQVTNVIITSSFASVLNYDKVADQSFIHTEKTWNPITWEQARVDEHAAYIASKTLAE KAAWDFVEKEKPSFELTTLLPPYIFGPQVFEDALQSGKLNTSCELINDVLKTNPGDGADDPTKFTKDGLLSVDVRDVALFHVLAFEKNLGNKRLFPVQGKFSQQAFLNIVNKDFPELKGKIATGTPQAAEDALKSYPAYDNSESAKLTGVQFIPLEKSVVDTVQQILHYKKKHGLPLK The gene sequence of the wild-type enzyme (SEQ ID NO.2): After the nucleotide sequence encoding PatCR_WT (SEQ ID NO.2) was synthesized by a gene synthesis company, it was linked to the expression vector pET-32a(+) to construct a wild-type carbonyl reductase expression vector, named pET-32a(+)-PatCR_WT.
[0052] The recombinant plasmid was transformed into Escherichia coli using a chemical transformation method. E. coli Rosetta2(DE3) competent cells were plated on solid plates containing 100 μg / mL ampicillin and 34 μg / mL chloramphenicol and incubated overnight at 37 °C to screen for wild-type recombinant bacteria. E. coli Rosetta2(DE3) / pET-32a(+)-PatCR_WT.
[0053] (2) Construction of expression vector and recombinant bacteria containing carbonyl reductase mutant Using the wild-type recombinant plasmid pET-32a(+)-PatCR_WT as a template, site-directed mutagenesis was performed using whole-plasmid PCR amplification with the primers described in Table 1. For two- or multi-site combined mutants (such as L247K-I171N, L247K-I171L, etc.), a new round of site-directed iterative mutagenesis was performed using the successfully constructed single- or multi-site mutant recombinant plasmids as templates.
[0054] The primer information for the core mutant is shown in Table 1: Table 1: Primer sequence information for constructing carbonyl reductase mutants
[0055] PCR reaction system (total volume 50 μL): PrimeSTAR Max DNA Polymerase 25 μL, sterile ddH2O 21 μL, template plasmid (concentration approximately 50 ng / μL) 2 μL, forward primer (10 μM) 1 μL, reverse primer (10 μM) 1 μL. PCR reaction conditions: 98 ℃ for 30 s, 98 ℃ denaturation for 10 s, 55 ℃ annealing for 5 s, 72 ℃ for 90 s, for a total of 30 cycles. The amplified PCR product was added to DpnI restriction endonuclease and digested at 37 ℃ for 1-2 h to completely degrade the methylated parental template plasmid.
[0056] The digested recombinant product was transformed into competent cells of the cloning host, plated, and single colonies were picked after culture. The recombinant plasmid was extracted and sent to a biotechnology company for sequencing verification. The mutant plasmid, which was verified by sequencing, was then transformed into the expression host again using chemical transformation. E. coliRosetta2(DE3) competent cells. Expression vectors containing different mutants and recombinant mutant bacteria were prepared through the above steps: E. coli Rosetta2(DE3) / pET-32a(+)-L247K、 E. coli Rosetta2(DE3) / pET-32a(+)-I171L、 E. coli Rosetta2(DE3) / pET-32a(+)-I171N、 E. coli Rosetta2(DE3) / pET-32a(+)-H167V、 E. coli Rosetta2(DE3) / pET-32a(+)-H167I、 E. coli Rosetta2(DE3) / pET-32a(+)-L247H、 E. coli Rosetta2(DE3) / pET-32a(+)-L247M、 E. coli Rosetta2(DE3) / pET-32a(+)-L247K-I171L、 E. coli Rosetta2(DE3) / pET-32a(+)-L247K-I171N、 E. coli Rosetta2(DE3) / pET-32a(+)-L247H-H167I、 E. coli Rosetta2(DE3) / pET-32a(+)-L247M-H167V、 E. coli Rosetta2(DE3) / pET-32a(+)-L247M-H167I.
[0057] Example 2: Induction and purification of wild-type and mutant carbonyl reductases (1) Induced expression of carbonyl reductase mutants and wild type The recombinant bacteria containing wild-type carbonyl reductase prepared in Example 1 E. coli Rosetta2(DE3) / pET-32a(+)-PatCR_WT and recombinant bacteria containing each mutant were inoculated into 5 mL of TB liquid medium containing 100 μg / mL ampicillin and 34 μg / mL chloramphenicol, respectively. Seed cultures were prepared by incubating in a constant temperature shaker at 37 ℃ and 200 r / min for 8–12 h.
[0058] The prepared seed culture was inoculated at a rate of 1% (v / v) into a 250 mL Erlenmeyer flask containing 50 mL of TB liquid medium (containing 100 μg / mL ampicillin and 34 μg / mL chloramphenicol). The flask was then incubated with shaking at 37 ℃ and 200 r / min until the OD of the bacterial culture reached a certain level. 600 The concentration was increased to 0.6-0.8. At this point, isopropyl-β-D-thiogalactoside (IPTG) was added to the culture system to a final concentration of 0.1 mM. Subsequently, a temperature change treatment was performed, lowering the culture temperature to 28°C and continuing the induction culture for 14 h to express the recombinant protein, and the fermentation broth was prepared.
[0059] (2) Preparation of crude enzyme solution and purification of target protein Preparation of crude enzyme solution: The fermentation broth was centrifuged at 4 ℃ and 8000 r / min for 10 min to collect the bacterial cells, which were then washed twice with pre-cooled physiological saline (or desalting buffer). The recombinant bacterial cells were resuspended in an appropriate amount of PBS buffer and subjected to sonication on ice (disruption parameters: power 400 W, sonication for 2 s, interval for 3 s, total sonication time 5 min). The resulting mixture was centrifuged in a refrigerated centrifuge to remove cell debris (centrifugation conditions: 4 ℃, 10000 r / min, centrifugation for 30 min). The supernatant collected after centrifugation was the crude enzyme solution containing carbonyl reductase.
[0060] Preparation of pure enzyme solution: For experiments requiring pure enzymes, the supernatant was filtered through a 0.22 μm aqueous filter membrane and then purified using a Ni-NTA affinity chromatography column. At 4 °C, the column was first washed with 5 column volumes of ultrapure water and PBS, followed by the injection of the filtered supernatant enzyme solution. Non-specifically bound proteins were washed away using elution buffer A (5 column volumes) containing a moderate concentration of imidazole. Subsequently, the target protein was collected using protein purification buffer B, and after desalting using a desalting column, pure enzyme solutions of wild-type and mutant strains were obtained.
[0061] SDS-PAGE protein gel electrophoresis showed that the recombinant proteins could be expressed efficiently in soluble form (Figure 2).
[0062] Example 3: Performance evaluation of carbonyl reductase in catalyzing β-tetrahydronaphthol (1) Construction of catalytic reaction system and sample pretreatment The crude enzyme solutions of the mutant enzyme and the wild-type enzyme prepared in Example 2 were subjected to an asymmetric reaction. An asymmetric reduction biocatalytic reaction system was constructed using the sterically hindered fused-ring compound β-tetrahydronaphthone as a substrate. A mixture with a final volume of 300 μL (50 μL NADPH solution + 50 μL substrate solution + 200 μL enzyme solution) was constructed in a 1 mL brown EP tube. The final concentration composition was: 100 mM PBS buffer (pH 7.2-7.4), 5 mM β-tetrahydronaphthone substrate, 5 mM coenzyme NADPH, and the crude enzyme solution obtained in Example 2 (final concentration of 0.1 g / mL).
[0063] Preparation of crude enzyme solution: The fermentation broth obtained in step (1) of Example 2 was centrifuged at 4 ℃ and 8000 r / min for 10 min to collect the cells, and washed twice with pre-cooled physiological saline (or desalting buffer). 0.5 g of recombinant cells were resuspended in 5 mL of PBS buffer and subjected to ultrasonic disruption under ice bath conditions (disruption parameters: power 400 W, ultrasonic operation for 2 s, interval for 3 s, total ultrasonic time 5 min). The mixture after disruption was centrifuged in a refrigerated centrifuge to remove cell debris (centrifugation conditions: 4 ℃, 10000 r / min, centrifugation for 30 min). The supernatant collected after centrifugation was the crude enzyme solution containing wild-type carbonyl reductase or its mutant, with a concentration of 0.1 g / mL.
[0064] The system was placed in a constant temperature shaking incubator at 30 ℃ and 200 r / min for 24 h.
[0065] After the reaction was complete, 3 volumes of ethyl acetate were added to quench and extract the mixture. After vigorous vortexing, the mixture was centrifuged at 10,000 r / min for 15 min. The upper organic phase was collected, dried over anhydrous sodium sulfate, and concentrated in a vacuum concentrator (10,000 r / min, 45℃) for 45 min. The concentrated phase was then redissolved in the mobile phase, vortexed thoroughly, and filtered through a 0.22 μm organic filter membrane for chromatographic analysis.
[0066] (2) Results and analysis of catalytic performance measurement Wild-type carbonyl reductase (WT) and the core mutant constructed in this invention were subjected to a catalytic reaction under the same conditions to prepare chiral β-tetrahydronaphthol (S-configuration / R-configuration). The combined results of conversion (yield) and stereoselectivity are shown in Table 2.
[0067] Table 2: Asymmetric reduction performance of wild-type and mutant β-tetrahydronaphthol
[0068] The results show: The carbonyl reductase mutants obtained through mutation can catalyze the asymmetric reduction of β-tetrahydronaphthone to generate the corresponding chiral β-tetrahydronaphthol. Specifically, L247K, I171L, I171N, L247K-I171L, L247K-I171N, L247H-H167I, L247M-H167V, and L247M-H167I tend to generate the S-configuration product, while H167V, H167I, L247H, and L247M tend to generate the R-configuration product.
[0069] Example 4: Determination of the specific activity of carbonyl reductase wild-type and core mutant To further evaluate the effect of the mutants of this invention on improving the initial catalytic reaction rate, the specific activity (U / mg) of purified wild-type carbonyl reductase (WT) and some core mutants was measured.
[0070] (1) Enzyme activity assay method Enzyme activity was measured by real-time monitoring of the rate of decrease in absorbance of the coenzyme NADPH at 340 nm using a microplate reader. The reaction system was preheated to 30 °C. The reaction system contained 100 mM PBS buffer (pH 7.2-7.4), 5 mM substrate β-tetrahydronaphthone, and 0.5 mM NADPH. Subsequently, 20 μL of the purified enzyme solution prepared in Example 2 (maintaining a final protein concentration of 0.50 mg / mL) was rapidly added to the system to initiate the reaction. The change in absorbance at 340 nm was continuously monitored, and the absorbance decrease during the initial linear reaction phase (e.g., within 1-3 min) was recorded.
[0071] The enzyme activity unit (U) is defined as follows: under the above standard determination conditions, the amount of enzyme that can reduce NADPH in the reaction system by 1 μmol per minute is defined as 1 enzyme activity unit, i.e., 1 U.
[0072] Specific activity (U / mg) = Measured enzyme activity (U) / Amount of protein added to the system (mg).
[0073] The concentration of the purified target protein was quantitatively calculated by measuring the absorbance at 280 nm using a micro spectrophotometer (such as NanoDrop) (A280 method).
[0074] (2) Results of enzyme activity assay The results of enzyme activity assays for wild-type and core mutants are shown in Table 3.
[0075] Table 3: Comparison of specific enzyme activities of wild-type and mutant carbonyl reductases
[0076] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.
Claims
1. A carbonyl reductase mutant, characterized in that, The carbonyl reductase mutant is obtained by performing any of the following mutations on the wild-type carbonyl reductase enzyme with the amino acid sequence shown in SEQ ID NO.1: The wild-type enzyme was mutated at position 247 to lysine, histidine, or methionine and named L247K, L247H, and L247M. Alternatively, the isoleucine at position 171 of the wild-type enzyme may be mutated to leucine or asparagine, and named as: I171L, I171N; Alternatively, the histidine at position 167 of the wild-type enzyme may be mutated to valine or isoleucine, and named: H167V, H167I. Alternatively, the leucine at position 247 of the wild-type enzyme may be mutated to lysine, and the isoleucine at position 171 may be mutated to leucine or asparagine, and named L247K-I171L and L247K-I171N. Alternatively, the leucine at position 247 of the wild-type enzyme may be mutated to histidine, and the histidine at position 167 may be mutated to isoleucine, named: L247H-H167I. Alternatively, the leucine at position 247 of the wild-type enzyme may be mutated to methionine, and the histidine at position 167 may be mutated to valine or isoleucine, and named L247M-H167V and L247M-H167I.
2. The gene encoding the carbonyl reductase mutant of claim 1.
3. A recombinant expression vector carrying the gene of claim 2.
4. Recombinant microbial cells expressing the carbonyl reductase mutant of claim 1, or carrying the gene of claim 2, or carrying the recombinant expression vector of claim 3.
5. The recombinant microbial cell according to claim 4, characterized in that, The recombinant microbial cells use bacteria or fungi as host cells; Preferably, the recombinant microbial cells use Escherichia coli as the host cell.
6. The use of the carbonyl reductase mutant of claim 1, or the gene of claim 2, or the recombinant expression vector of claim 3, or the recombinant microbial cell of claim 4 or 5 in the catalytic asymmetric reduction of β-tetrahydronaphthol to prepare chiral β-tetrahydronaphthol.
7. A method for preparing chiral β-tetrahydronaphthol with high activity, characterized in that, The method is as follows: the carbonyl reductase mutant of claim 1, or the recombinant microbial cell of claim 4 or 5, is added to a reaction system containing the substrate β-tetrahydronaphthone to prepare chiral β-tetrahydronaphthol; When the carbonyl reductase mutant is a single-point mutation L247K, I171L, I171N, or a combination mutation L247K-I171L, L247K-I171N, L247H-H167I, L247M-H167V, L247M-H167I, the product generated is (S)-β-tetrahydronaphthol. When the carbonyl reductase mutant is a single-point mutation H167V, H167I, L247H, or L247M, an absolute configuration inversion occurs, and the product is (R)-β-tetrahydronaphthol.
8. The preparation method according to claim 7, characterized in that, The concentration of the substrate β-tetrahydronaphthone in the reaction system is 5-10 mM; Preferably, the reaction system further contains coenzyme NADPH and a buffer solution; the concentration of coenzyme NADPH is 5-10 mM, and the buffer solution is 100 mM PBS buffer with a pH of 6.0-8.
5. Preferably, the reaction conditions are: constant temperature shaking reaction at 25-35 ℃ and 200 rpm for 12-36 hours.
9. A method for overcoming the steric confinement of a highly hindered substrate in the wild-type catalysis of carbonyl reductase and achieving configuration inversion, characterized in that, The method is as follows: the carbonyl reductase mutant is a mutation of the wild-type carbonyl reductase with the amino acid sequence shown in SEQ ID NO.1, wherein the mutation is as follows: leucine at position 247 of the wild-type enzyme is mutated to lysine, histidine, or methionine; or isoleucine at position 171 of the wild-type enzyme is mutated to leucine or asparagine; or histidine at position 167 of the wild-type enzyme is mutated to valine or isoleucine; or leucine at position 247 of the wild-type enzyme is mutated to lysine, and isoleucine at position 171 is mutated to leucine or asparagine; or leucine at position 247 of the wild-type enzyme is mutated to histidine, and histidine at position 167 is mutated to isoleucine; or leucine at position 247 of the wild-type enzyme is mutated to methionine, and histidine at position 167 is mutated to valine or isoleucine.
10. The use of the carbonyl reductase mutant of claim 1, or the gene of claim 2, or the recombinant expression vector of claim 3, or the recombinant microbial cell of claim 4 or 5 in the preparation of a drug or a drug intermediate; wherein the drug or drug intermediate includes, but is not limited to, liranafate, udimide, MK-0499, 5,6,7,8-tetrahydro-2-naphthol, (S)-2-tetrahydronaphthol, 6-hydroxy-2-tetrahydronaphthol, 2-aminotetrahydronaphthol, rotigotine, AR-A2, quinagolide, naphthone derivatives, or tetrahydronaphth-2-ol derivatives.
